However, the tumor-specific reliance on the PREX2-AHCYL1 axis, as evidenced by different MEK/ERK and PI3K/AKT signaling response in NL20 and NSCLC cells after AHCYL1 knockdown, suggests a potential therapeutic window. Here, MAP2K7 is linked to non-small cell lung carcinoma.